Table 3.
Description of the CHMI and infection outcomes.
| Phase | Group | Code | Doses | Mosquitoes | Prepatent period (days) | Parasite/μL (microscopy) | |
|---|---|---|---|---|---|---|---|
| Bitesb | Spzc | ||||||
| IIa | NAIVE | CS1001 | 3 | 4 | 32 | 14 | 120 |
| CS1006 | 3 | 2 | 32 | 16 | 100 | ||
| CS1013 | 3 | 2 | 32 | 17 | 100 | ||
| CS1015 | 3 | 2 | 32 | 15 | 100 | ||
| CS1023 | 3 | 3 | 22 | 16 | 80 | ||
| CS1025 | 3 | 2 | 25 | 16 | 60 | ||
| CS1028 | 3 | 3 | 22 | 16 | 280 | ||
| CS1030 | 3 | 3 | 46 | P | 0 | ||
| CS1031 | 3 | 2 | 10 | P | 0 | ||
| CS1036 | 3 | 2 | 100 | P | 0 | ||
| CS1038 | 3 | 2 | 100 | P | 0 | ||
| CONTROL | CS1003 | 3 | 3 | 215 | 16 | 400 | |
| CS1005 | 3 | 2 | 32 | 16 | 100 | ||
| CS1012 | 3 | 3 | 100 | 15 | 220 | ||
| CS1018 | 3 | 3 | 32 | 16 | 240 | ||
| CS1037 | 3 | 3 | 22 | 16 | 100 | ||
| CS1016 | 2a | NA | NA | NA | NA | ||
| IIb | SEMI-IMMUNE | CS1506 | 3 | 2 | 100 | 12 | 60 |
| CS1511 | 3 | 2 | 32 | P | 0 | ||
| CS1535 | 3 | 2 | 100 | P | 0 | ||
| CS1537 | 3 | 2 | 316 | 19 | 20 | ||
| CS1538 | 3 | 2 | 1000 | 15 | 60 | ||
| CS1547 | 3 | 2 | 32 | P | 0 | ||
| CS1553 | 3 | 3 | 22 | 19 | 400 | ||
| CS1565 | 3 | 3 | 100 | 15 | 160 | ||
| CS1569 | 3 | 2 | 100 | 16 | 340 | ||
| CS1575 | 3 | 2 | 100 | 14 | 128 | ||
| CS1581 | 3 | 2 | 10,000 | 17 | 60 | ||
| CS1584 | 1a | 2 | NA | NA | NA | ||
| CONTROL | CS1549 | 3 | 4 | 56 | 17 | 50 | |
| CS1554 | 3 | 2 | 100 | 16 | 400 | ||
| CS1570 | 3 | 3 | 22 | 17 | 70 | ||
| CS1572 | 3 | 2 | 1000 | P | 0 | ||
| CS1574 | 3 | 2 | 32 | 17 | 220 | ||
| CS1579 | 1a | 2 | NA | NA | NA | ||
P protected, NA not apply.
aWithdraws.
bNo. of infected mosquitoes.
cSpz density.